期刊文献+

新型带状疱疹重组亚单位疫苗Shingrix的研究进展

Progress in research on a novel recombinant varicella zoster virus subunit vaccine Shingrix
收藏 分享 导出
摘要 人类是水痘-带状疱疹病毒(varicella zoster virus,VZV)唯一的宿主,首次感染表现为水痘或呈隐性感染,病毒可延轴突上行,潜伏在感觉神经节内,通常终身潜伏,当机体免疫功能降低时,VZV可被重新激活,引发带状疱疹。Shingrix是一种新型带状疱疹重组亚单位疫苗,主要成分为重组VZV糖蛋白E(gE)和佐剂系统AS01B,美国FDA于2017年10月批准用于年龄≥50岁成年人带状疱疹的预防。Shingrix可有效强化VZV特异性免疫,预防带状疱疹及其并发症。本文对Shingrix的药理作用、适应证、用法用量、不良反应、特殊人群用药等内容作一综述。 Human being is the only host of varicella zoster virus (VZV). The first infection with the virus may cause varicella or is in latency,in which the virus may ascend along the axon and latent in the sensory ganglion,resulting in lifelong latency in general. When the immune function is depressed,VZV may be reactivated and result in zoster. Shingrix is a novel recombinant subunit vaccine containing VZV glycoprotein E and the AS01B adjuvant system,which was approved by the FDA in October 2017 for the prevention of herpes zoster in adults at ages of not less than 50 years. Shingrix can effectively strengthen the specific immunity of VZV and prevent varicella zoster as well its complication. This paper reviews the pharmacology,indications,usage and dosage as well as adverse reactions and administration in specific populations of Shingrix.
作者 范婷 李新刚(综述) 赵志刚(审校) FAN Ting;LI Xin-gang;ZHAO Zhi-gang(Department of Pharmacy,Beijing Tiantan Hospital Affiliated to Capital Medical University,Beijing 100050,China)
出处 《中国生物制品学杂志》 CAS CSCD 2019年第7期814-818,共5页 Chinese Journal of Biologicals
基金 国家自然科学基金(81503157).
关键词 带状疱疹 重组亚单位疫苗 Herpes zoster Recombinant subunit vaccine
作者简介 通讯作者:赵志刚,E-mail:1022zzg@sina.com.
  • 相关文献

参考文献3

二级参考文献150

  • 1刘太华,张忠奎,许泽娟,罗陈.带状疱疹临床流行病学分析[J].西南军医,2005,7(6):28-30. 被引量:24
  • 2吴寰宇,张爱香,任宏,李燕婷.上海市部分地区儿童水痘疫苗免疫后流行病学效果观察[J].上海预防医学,2006,18(9):437-439. 被引量:40
  • 3张延龄,张晖,戴科.疫苗学[M].北京:科学出版社,2006. 被引量:14
  • 4王敏力,沈琦.水痘-带状疱疹免疫球蛋白研究进展[J].中国生物制品学杂志,2007,20(9):701-704. 被引量:11
  • 5American Academy of Pediatrics.Section 3.Summaries of Infectious Diseases.In:Pickering LK,Baker CJ,Long SS,et al,eds.Red Book:2006 Report of the Committee on Infectious Diseases.27th ed.Elk Grove Village,IL:American Academy of Pediatrics,2006.711-725. 被引量:1
  • 6Hambleton S,Gershon AA.Preventing varicella-zoster disease.Clin Microbio Rev,2005,18(1):70-80. 被引量:1
  • 7Grant RM,Weitzman SS,Sherman CG,et al.Fulminant disseminated varicella zoster virus infection without skin involvement.J Clin Virol,2002,24(1-2):7-12. 被引量:1
  • 8Stratman E.Visceral zoster as the presenting feature of disseminated herpes zoster.J Am Acad Dermatol,2002,46(5):771-774. 被引量:1
  • 9Koren G,Money D,Boucher M,et al.Serum concentrations,efficacy,and safety of a new,intravenously administered varicella zoster immune globulin in pregnant women.J Clin Pharmacol,2002,42(3):267-274. 被引量:1
  • 10Casadevall A,Dadachova E,Pirofski LA.Passive antibody therapy for infectious diseases.Nat Rev Microbiol,2004,2(9):695-703. 被引量:1

共引文献201

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈